JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY) ›› 2016, Vol. 30 ›› Issue (4): 43-49.doi: 10.6040/j.issn.1673-3770.0.2016.224

Previous Articles     Next Articles

Predictive biomarkers for dust mite specific immunotherapy in patients with allergic rhinitis.

ZHOU Wencheng, YUAN Yuan, CHENG Lei   

  1. Department of Otorhinolaryngology, The First Affiliated Hospital, Nanjing Medical University, Nanjing 210029, Jiangsu, China
  • Received:2016-05-15 Online:2016-08-16 Published:2016-08-16

PDF (PC)

1655

Abstract: Objective To investigate the changes of serum total IgE(tIgE)and specific IgE(sIgE)levels in patients with allergic rhinitis(AR)one year after allergen-specific immunotherapy, and so as to explore the predictive biomarkers for therapeutic effects of subcutaneous immunotherapy(SCIT)and sublingual immunotherapy(SLIT). Methods Patients with moderate-to-severe persistent AR who completed one year of dust mite specific immunotherapy were enrolled in this study. The effectiveness of immunotherapy was evaluated by patient-reported outcomes. The changes of serum tIgE, Dp-sIgE and Df-sIgE levels were compared before and after immunotherapy, and these antibody levels were stratified analyzed based on the responders and nonresponders of treatment. The baseline serum IgE levels before immunotherapy were tested for correlation with clinical response to the treatment, and the best predictive biomarkers and cut-off value for discriminating between responders and nonresponders were estimated on the basis of the receiver operator characteristic(ROC)curve. Results The effective rate of the SCIT group(n=50)and the SLIT group(n=58)was 64% and 65.5% after one year immunotherapy, respectively. And there was no statistical significant difference between the two groups(P>0.05). Also, no significant differences in the levels of tIgE, Dp-sIgE and Df-sIgE were observed in both groups before and after immunotherapy(P>0.05). However, a significant decreased serum Dp-sIgE level was found in the responders of treatment in the SCIT group. The using of baseline serum Dp-sIgE/tIgE ratio > 11.95% as a biomarker of effective SCIT yielded a sensitivity value of 71.9% and a specificity of 83.3%. As for SLIT, the serum Df-sIgE levels > 27.95 IU/ml(grade 4)yielded a sensitivity value of 52.6% and a specificity of 85.0%. Conclusion Serum sIgE level before immunotherapy could be a useful biomarker for predicting response to the treatment. Generally, patients with higher levels of sIgE or sIgE/tIgE ratios may be more likely to achieve therapeutic effect.

Key words: Allergic rhinitis, Immunotherapy, Biomarkers, Receiver operating characteristic curve, Immunoglobulin E

CLC Number: 

  • R765.21
[1] Zhang Y, Zhang L. Prevalence of allergic rhinitis in China[J]. Allergy Asthma Immunol Res, 2014, 6(2):105-113.
[2] 程雷. 变应性鼻炎的特异性免疫治疗[J]. 山东大学耳鼻喉眼学报, 2011, 25(5):33-35.
[3] 程雷. 舌下免疫治疗在中国的临床应用及若干问题探讨[J]. 中华耳鼻咽喉头颈外科杂志, 2015, 50(8):617-618.
[4] 中华耳鼻咽喉头颈外科杂志编委会鼻科组,中华医学会耳鼻咽喉头颈外科学分会鼻科学组. 变应性鼻炎特异性免疫治疗专家共识[J]. 中华耳鼻咽喉头颈外科杂志, 2011, 46(12):976-980.
[5] Jutel M, Agache I, Bonini S, et al. International consensus on allergy immunotherapy[J]. J Allergy Clin Immunol, 2015, 136(3):556-568.
[6] Canonica G W, Cox L, Pawankar R, et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update[J]. World Allergy Organ J, 2014, 7(1):6.
[7] Walker S M, Durham S R, Till S J, et al. Immunotherapy for allergic rhinitis[J]. Clin Exp Allergy, 2011, 41(9):1177-1200.
[8] 中华医学会耳鼻咽喉头颈外科学分会鼻科学组,中华耳鼻咽喉头颈外科杂志编辑委员会鼻科组. 变应性鼻炎诊断和治疗指南(2015年,天津)[J]. 中华耳鼻咽喉头颈外科杂志, 2016, 51(1):6-24.
[9] 中华耳鼻咽喉头颈外科杂志编委会鼻科组,中华医学会耳鼻咽喉头颈外科学分会鼻科学组. 变应性鼻炎诊断和治疗指南(2009年,武夷山)[J]. 中华耳鼻咽喉头颈外科杂志, 2009, 44(12):977-978.
[10] Bergmann K C, Demoly P, Worm M, et al. Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis[J]. J Allergy Clin Immunol, 2014, 133(6):1608-1614.
[11] Bousquet J, Khaltaev N, Cruz A A, et al. Allergic Rhinitis and its Impact on Asthma(ARIA)2008 update(in collaboration with the World Health Organization, GA(2)LEN and AllerGen)[J]. Allergy, 2008, 63 Suppl 86:8-160.
[12] Brozek J L, Bousquet J, Baena-Cagnani C E, et al. Allergic Rhinitis and its Impact on Asthma(ARIA)guidelines: 2010 revision[J]. J Allergy Clin Immunol, 2010, 126(3):466-476.
[13] Ciprandi G, Tosca M A, Silvestri M. The practical role of serum allergen-specific IgE as potential biomarker for predicting responder to allergen immunotherapy[J]. Expert Rev Clin Immunol, 2014, 10(3):321-324.
[14] de Bot C M, Moed H, Berger M Y, et al. Sublingual immunotherapy not effective in house dust mite-allergic children in primary care[J]. Pediatr Allergy Immunol, 2012, 23(2):150-158.
[15] Zuberbier T, Bachert C, Bousquet P J,et al. GA2LEN/EAACI pocket guide for allergen-specific immunotherapy for allergic rhinitis and asthma. Allergy, 2010, 65(12):1525-1530.
[16] Chelladurai Y, Suarez-Cuervo C, Erekosima N, et al. Effectiveness of subcutaneous versus sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review[J]. J Allergy Clin Immunol Pract, 2013, 1(4):361-369.
[17] Okubo K, Kurono Y, Fujieda S, et al. Japanese Guideline for Allergic Rhinitis 2014[J]. Allergol Int, 2014, 63(3):357-375.
[18] Seidman M D, Gurgel R K, Lin S Y, et al. Clinical practice guideline: Allergic rhinitis[J]. Otolaryngol Head Neck Surg, 2015, 152(Suppl 1):S1-S43.
[19] Yukselen A, Kendirli S G, Yilmaz M, et al. Effect of one-year subcutaneous and sublingual immunotherapy on clinical and laboratory parameters in children with rhinitis and asthma: a randomized, placebo-controlled, double-blind, double-dummy study[J]. Int Arch Allergy Immunol, 2012, 157(3):288-298.
[20] Radulovic S, Wilson D, Calderon M, et al. Systematic reviews of sublingual immunotherapy(SLIT)[J]. Allergy, 2011, 66(6):740-752.
[21] Akdis C A, Akdis M. Mechanisms of allergen-specific immunotherapy and immune tolerance to allergens[J]. World Allergy Organ J, 2015, 8(1):17.
[22] Zhao D, Lai X, Tian M, et al. The functional IgE-blocking factor induced by allergen-specific immunotherapy correlates with IgG4 antibodies and a decrease of symptoms in house dust mite-allergic Children[J]. Int Arch Allergy Immunol, 2016, 169(2):113-120.
[23] Shamji M H, Ljorring C, Francis J N, et al. Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy[J]. Allergy, 2012, 67(2):217-226.
[24] Calderon M, Cardona V, Demoly P. One hundred years of allergen immunotherapy European Academy of Allergy and Clinical Immunology celebration: review of unanswered questions[J]. Allergy, 2012, 67(4):462-476.
[25] Tosca M, Silvestri M, Accogli A, et al. Serum-specific IgE and allergen immunotherapy in allergic children[J]. Immunotherapy, 2014, 6(1):29-33.
[26] Ciprandi G, Silvestri M. Serum specific IgE: a biomarker of response to allergen immunotherapy[J]. J Investig Allergol Clin Immunol, 2014, 24(1):35-39.
[27] Di Lorenzo G, Mansueto P, Pacor M L, et al. Evaluation of serum s-IgE/total IgE ratio in predicting clinical response to allergen-specific immunotherapy[J]. J Allergy Clin Immunol, 2009, 123(5):1103-1110.
[28] 刘靖,张晓波,冯海燕,等. 影响儿童哮喘尘螨特异性免疫疗效的因素分析[J]. 中国当代儿科杂志, 2013, 15(10):854-859. LIU Jing, ZHANG Xiaobo, FENG Haiyan, et al. Impact factors for efficacy of specific immunotherapy in children with dust mite allergic asthma[J]. Chin J Contem Pedia, 2013, 15(10):854-859.
[1] LYU Qian, TANG Yuan, GU Zijun, SHI Sailei, LIU Ping, WAN Wenjin. Current status of benefit finding among patients with allergic rhinitis and its influence factors [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2026, 40(1): 21-28.
[2] SUN Qingzhu, SHEN Jian, CHEN Xing, WU Yanbing, ZENG Lun. The role of metabolic indicators in predicting ranibizumab efficacy in diabetic macular edema [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2026, 40(1): 74-81.
[3] GU Min, LU Meiping. Advances in the application of nanomedicine delivery systems in allergen immunotherapy for allergic rhinitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2026, 40(1): 106-111.
[4] QIN Nana, LI Yufen, SUN Yuhao, WEI Jian, LI Qin. Effect of interleukin-13 receptor-α2 on nasal mucosal remodeling in rats with allergic rhinitis by TGF-β1/Smad signaling pathway [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(6): 71-77.
[5] DU Kangli, ZHENG Zhenyu, XU Zhanjiang, ZHANG Yu, CHEN Lu, LU Mengyao. Construction and validation of risk prediction model for nasal septal deviation complicated with chronic sinusitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(6): 78-86.
[6] XIONG Qin, ZHANG Yan, WU Rina, LI Feng, TANG Lixing. Application of intranasal corticosteroids in pediatrics [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(6): 160-167.
[7] XU Xuemeng, FAN Lei, YU Wangbo, JIANG Zhiyue, PAN Chen, HUANG Yongqin. Meta-analysis of the efficacy of omalizumab in combination with specific immunotherapy for allergic rhinitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(5): 26-33.
[8] HUANG Huan, HUA Hongli, DENG Yuqin, JIANG Chengyang, WANG Yuwei, YANG Xinghai. Correlation of allergic rhinitis, tonsil adenoid hypertrophy, and sinusitis in children and analysis of its clinical guiding value [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(5): 34-41.
[9] LIU Yijun, GU Yue, GUAN Dayu, YANG Yucheng, SHEN Yang. The long-term clinical efficacy and safety of vidian neurectomy in refractory allergic rhinitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(5): 42-48.
[10] YIN Zhenqian, HUANGFU Hui. Kimura disease:a case report and literature review [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(5): 104-107.
[11] ZHANG Ting, WANG Meilan, GAO Yingqin. Research progress of IL-35 in allergic rhinitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(5): 139-147.
[12] ZHANG Zhuping, PENG Zican, XIAO Zhenlong, LI Cheng, YU Di, WANG Xinglong, CHEN Wei, Guo Bei. The value of a novel nasal secretion eosinophil cationic protein-myeloperoxidase test paper assay in allergic rhinitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(3): 129-134.
[13] LIU Chang, YANG Jingpu, GAO Yu, WANG Wenjia. Analysis of allergen detection results in children with allergic rhinitis in the Changchun area [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(2): 51-58.
[14] ZHOU Heqing, SHEN Qi. Research progress on biomarkers of traditional Chinese medicine in the treatment of allergic rhinitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(2): 168-176.
[15] ZHANG Yunqiu, REN Xiumin, XU Ou, DONG Jinhui, WANG Jianxing. Research progress on omalizumab targeted therapy for chronic sinusitis with nasal polyps [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(1): 136-140.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Website Copyright: Editorial Office of Journal of Otolaryngology and Ophthalmology of Shandong University
Address: No.27 Shanda South Road, Jinan, Shandong, China. Post code: 250100 Tel: +86-0531-88366912 Email: ebhxb@sdu.edu.cn Supported by Beijing Magtech Co.Ltd